Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
SINGAPORE, Sept. 10, 2026 /PRNewswire/ -- Novo Holdings, a leading global healthcare and life sciences investor, today announced a strategic minority investment in Huizhou ForYou Medical Devices Co., Ltd. ("ForYou Medical"), a China-based contract development and manufacturing organisation (CDMO) specialising in advanced wound care products. GL Capital, one of China's leading healthcare-focused private equity firms, will remain the company's...
CordenPharma Boosts Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Per Year
CordenPharma accelerates sterile injectable CDMO manufacturing expansion with €80 million multi-year investment in new facility and additional aseptic fill & finish lines BASEL, Switzerland, Sept. 10, 2026 /PRNewswire/ -- CordenPharma continues its ambitious long-term injectable CAPEX program at its FDA & EMA-approved Caponago (Milan), Italy site, reinforcing its position as a...
Dymax Launches BlueWave® FX Line Emitters to Boost Throughput in High-Speed Linear UV/Visible Curing
- New 75 mm and 150 mm line emitters deliver up to 4.2 W/cm² with 365/385/405 nm options and FX controller compatibility for scalable automation. SINGAPORE, Sept. 10, 2026 /PRNewswire/ -- Dymax, a global manufacturer of light-curing materials and equipment, today announced the BlueWave® FX Line Emitter series, purpose-built to deliver fast, uniform linear UV/Visible exposure in automated...
BGI Genomics Launches “Digital Life Twin” Framework to Power Proactive Health
SHENZHEN, China, Sept. 9, 2026 /PRNewswire/ -- Commemorating BGI Group's 27th anniversary, BGI Genomics today introduced its Digital Life Twin framework alongside an advanced multi-omics diagnostic portfolio at the 2026 Global New Product Launch Event. Grounded in over two decades of population-scale genetic discoveries, the launch marks a decisive transition from traditional, reactive diagnostics to continuous, predictive health...
Yuyu Pharma CEO Robert Wonsang Yu Launches “Robert’s YUniverse” Podcast
SEOUL, South Korea, Sept. 9, 2026 /PRNewswire/ -- Robert Wonsang Yu, CEO of Yuyu Pharma, has launched "Robert's YUniverse", a new podcast series featuring conversations with guests from across culture, business and animal health. Hosted by Robert Wonsang Yu, the podcast explores subjects including Korean culture, Korean cuisine and...
First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA
BEIJING and BRIDGEWATER, Mass., Sept. 9, 2026 /PRNewswire/ -- Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH) Phase 1 study of GZC8072 tablets, a novel ultra-long-acting oral peptide GLP-1 RA formulated for once-weekly administration. This milestone marks the formal entry of this innovative candidate into clinical...
Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept. 9, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Defense company Covenant has...
Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial
LONDON, Sept. 9, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New Drug ("IND") application for Ac-FL-261 and that the program has received Australian Human Research Ethics Committee ("HREC") approval and completed the Clinical...
Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies
PRINCETON, N.J. and SUZHOU, China, Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its subsidiary, HJB, have entered into a technology licensing and strategic collaboration agreement with WuXi Biologics. Under the agreement, Transcenta will grant...
Daesang Targets Global Pharmaceutical Amino Acid Market, Building on 70 Years of Fermentation Technology
Leverages fermentation know-how developed through MIWON to expand beyond general-purpose amino acids into high-value pharmaceutical materials Acquires Germany-based AMINO GmbH, gaining purification technology, European regulatory expertise, and a global customer network SEOUL, South Korea, Sept. 9, 2026 /PRNewswire/ -- Daesang, a Korean food and biotechnology company, is...
